Y. Nakamura et al., Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge, J ALLERG CL, 105(6), 2000, pp. 1146-1152
Background: Allergic rhinitis is a complex upper airways disorder character
ized by the infiltration of eosinophils and T-H2-type T lymphocytes. GATA-3
is a novel transcription factor recently shown to regulate IL-5 and, possi
bly, IL-4 gene expression. We previously reported that GATA-3 is increased
within the bronchial mucosa of allergic asthmatic subjects compared with co
ntrol subjects.
Objective: In the present study we set out to determine whether there is al
so an increased number of cells expressing GATA-3 messenger (m)RNA within t
he nasal mucosa of patients with allergic rhinitis.
Methods: Inferior turbinate biopsy specimens mere obtained from patients wi
th allergic rhinitis and nonatopic control subjects before and after local
allergen provocation in vivo. To assess the contribution of resident cells
expressing GATA-3 mRNA, we also performed isolated explant studies in which
nasal mucosal tissue from subjects with allergic rhinitis and nonatopic co
ntrol subjects was cultured in allergen-treated medium The presence of mRNA
coding for GATA-3, IL-5, IL-4, IL-13, and GM-CSF was assessed by using in
situ hybridization.
Results: The number of GATA-3 mRNA(+) cells was increased after local aller
gen provocation in vivo (increase in GATA-3 mRNA(+) cells [mean +/- SEM]: s
ubjects,vith allergic rhinitis, 11.3 +/- 8.7; control subjects, 1.2 +/- 4.1
; P < .05) and in explanted nasal mucosa in vitro (subjects with allergic r
hinitis, 10.2 +/- 3.8; control subjects, 2.7 +/- 4.4; P < .05). The gene ex
pression of GATA-3 was significantly correlated to the numbers of IL-5 (r =
0.87) and GM-CSF (r = 0.79) mRNA(+) cells but not with IL-4 or IL-13 mRNA(
+) cells.
Conclusion: In summary, the expression of the transcription factor GATA-3 w
as increased after allergen challenge, and this was evident in the absence
of de novo inflammatory cell recruitment. GATA-3 may be a potential target
in the treat ment of allergic diseases, such as rhinitis.